CJC-1295 Ipamorelin

About · who writes this and how

About this site: the CJC-1295 ipamorelin record, read in full

Disclosure: the publisher of this site also runs the OXpeptides shop, cited on these pages.

Published 21 Sep 2026Updated 25 Sep 20264 min read
sources, each read in full
34
DOI or trial number checked
28
testimonials, pixels or ads
0

Figure 1

The 34 sources cited on this site

Every DOI and trial number resolved on its registry before publication; a reference that does not answer is not cited. Each guide lists its own sources at the end of the page.

Method

Each article starts from the primary literature, not from other websites. For CJC-1295 that is the ConjuChem chemistry paper of 2005 and the two Journal of Clinical Endocrinology and Metabolism trials of 2006; for ipamorelin it is the Novo Nordisk paper of 1998, the pharmacokinetic study of 1999 and the phase 2 trials registered by Helsinn; for the GHRH plus GHRP principle it is the 1990 study by Bowers and Thorner. Abstracts are read from PubMed; registry entries are read from the ClinicalTrials.gov API. When a figure is quoted, it is the figure in the abstract or the registry entry, in the units the authors used.

Before publication, every DOI on the site is requested from the CrossRef API at api.crossref.org and every trial number from the ClinicalTrials.gov API; a reference that does not return HTTP 200 is not cited. As of the last check, the site cites 34 sources, 26 of them with a DOI and 5 with a registry number. Regulatory statements point to the FDA and WADA pages they come from.

What the site will not do

  • It gives no doses, schedules or protocols. It reports what the published studies measured, with the DOI beside each figure.
  • It does not publish testimonials, reviews, before-and-after accounts or personal results, because none exist in the literature for these molecules and inventing them would be a lie.
  • It does not describe effects on muscle, fat, sleep or recovery for CJC-1295 ipamorelin, because no human study has measured them.
  • It carries no analytics, no advertising pixel and no third-party script.

The publisher of this site also runs the OXpeptides shop: that is a conflict of interest, stated here and on every page. The product link on every page goes to the CJC-1295 / ipamorelin blend at oxpeptides.com, sold for research use only and shipped within Europe: a purity specification above 99 % by HPLC and a named laboratory, Janoshik (report for this product pending, published with its verification key as soon as it comes back).

Corrections

Errors are corrected on the page where they occur, with the updated date changed, and a note is added at the foot of the page when the correction changes a figure. Reports go to contact@cjc-1295-ipamorelin.com; a report that cites a DOI or an NCT number is answered first. The full policy is on the editorial policy page.

Who

The site is written and maintained by its editorial desk, part of the company that also runs OXpeptides. It does not publish personal bylines: every article is signed by the editorial desk, whose page lists what it reads, how it checks each reference and every guide it maintains. Corrections and questions go to the address above.

All 6 guides

Informational content, not medical advice. CJC-1295 and ipamorelin are investigational research compounds, not approved by the FDA or the EMA for any use, sold for research use only, not for human or veterinary use.